Health-related quality of life of multisystem atrophy and progressive supranuclear palsy patients
Objective: The aim of our study was to describe how different aspects of daily living and health related quality of life (HRQoL) are impaired by…[18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer’s disease
Objective: To evaluate: (1) brain tau pathology in vivo in patients with Progressive Supranuclear Palsy (PSP) and Alzheimer's disease (AD); (2) whether brain tau pathology…Comparison of cognitive and neuropsychological manifestations in patients with progressive supranuclear palsy (Psp) and Parkinson’s disease
Objective: 1) To compare the cognitive and neuropsychological manifestations between the patients with PSP and PD. 2) To find out the severity of caregivers distress…An elderly patient presenting as pure akinesia with gait freezing (PAGF): Idiopathic aqueductal stenosis-associated hydrocephalus
Objective: Pure akinesia with gait freezing (PAGF)-mimicking disorders remain to be further elucidated. Background: Hydrocephalus is a poorly elucidated disorder. Aqueductal stenosis (AS) is a…Initial clinical description of progressive supranuclear palsy in the Luxembourg Parkinson’s study
Objective: To characterize the clinical features and prevalence of patients with progressive supranuclear palsy (PSP) in the recently implemented longitudinal Parkinson's cohort (HELP-PD). Background: PSP…PET imaging of tau pathology in progressive supranuclear palsy
Objective: This study aimed to determine whether there is an increase in [18F]-AV-1451 uptake in the brains of progressive supranuclear palsy (PSP) patients compared to…Non-motor symptoms in progressive supranuclear palsy
Objective: To explore the clinical correlates of Non-motor symptoms (NMS) in progressive supranuclear palsy (PSP) and their differences from healthy aging and Parkinson's disease (PD).…A cross-sectional study of sensor-based gait analysis in atypical Parkinsonian disorders
Objective: Primary objective was to identify quantitative markers of gait impairment in patients with idiopathic Parkinson's disease (IPD), atypical Parkinsonian disorders (APD) and healthy controls…Low cerebrospinal fluid 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxyphenylglycol levels are biomarkers of Parkinsonian disorders, including PSP
Objective: To assess whether Progressive Sopranuclear Palsy (PSP) patients show, in CSF an alteration of catecholamine metabolites. Background: It was reported previously that, consistent with…Evaluation of the surface based measures to discriminate progressive supranuclear palsy from corticobasal syndrome
Objective: To evaluate structural gray matter (GM) changes tested by surface-based measures of cortical thickness (CTh), surface area (SA) and volume (VOL), in order to…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.